Scientists have long known that dopamine helps the brain learn from rewards, but a new computational model shows how for ...

A genetic postmortem analysis of the brains of patients with schizophrenia suggests dysfunction of dopamine receptors in the caudate nucleus may cause the disorder. Investigators identified a ...

Researchers at the University of Illinois Urbana-Champaign have traced a genetic mutation found in psychosis patients to a ...

Researchers have found statistically significant links between a gene tied to schizophrenia risk and poorer cognitive ...

Researchers say discovery could establish the basis for a novel, tandem biomarker-peptide therapeutic approach to ...

Schizophrenia risk may reflect two brain pathways with different cortical and subcortical balance. Early language learning relies more on subcortical systems; later learning engages cortical control.

Minerva Neurosciences (NASDAQ:NERV) provided an update on its development program for roluperidone, which the company ...

Please provide your email address to receive an email when new articles are posted on . Cobenfy is the first antipsychotic medication to treat schizophrenia by targeting cholinergic receptors. The ...

How Does Cobenfy Work, and How Is It Different From Other Medicines Used to Treat Schizophrenia? An imbalance of brain chemicals called neurotransmitters may contribute to schizophrenia. Current ...

The general consensus among experts is that TRS is a condition in which an individual’s symptoms haven’t responded to two or more antipsychotic medicines given at a therapeutic dose for at least six ...